Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Monopar Therapeutics from “sell” to “hold,” while the broader analyst consensus remains “Buy,” with three Strong Buy ratings, ten Buy ratings and a $112.08 average price target.
• MNPR shares were trading at $119.21, down 0.8%, near their 12-month high of $124.82; the company reported quarterly EPS of negative $0.46, beating the consensus estimate of negative $0.87.
• Several institutional investors increased their positions, including RA Capital Management, Siren L.L.C. and ADAR1 Capital Management, though institutional investors collectively own only 1.83% of the stock.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday.

A number of other equities analysts have also recently weighed in on MNPR. Zacks Research raised shares of Monopar Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Monday, July 13th. Cantor Fitzgerald restated an "overweight" rating on shares of Monopar Therapeutics in a research note on Wednesday, July 15th. BTIG Research raised their price target on Monopar Therapeutics from $104.00 to $117.00 and gave the stock a "buy" rating in a research report on Tuesday, June 30th. HC Wainwright lifted their price objective on Monopar Therapeutics from $105.00 to $125.00 and gave the company a "buy" rating in a research note on Wednesday, July 22nd. Finally, Piper Sandler set a $105.00 price objective on Monopar Therapeutics in a report on Tuesday, June 2nd. Three research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $112.08.

Monopar Therapeutics Trading Down 0.8%

Shares of MNPR opened at $119.21 on Friday. The firm has a market cap of $798.71 million, a P/E ratio of -62.74 and a beta of 1.47. Monopar Therapeutics has a 12-month low of $29.18 and a 12-month high of $124.82. The company's 50-day moving average price is $90.83 and its 200 day moving average price is $70.05.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.41. Equities research analysts forecast that Monopar Therapeutics will post -2.82 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in MNPR. Janus Henderson Group PLC lifted its holdings in Monopar Therapeutics by 2.3% during the 4th quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company's stock worth $85,908,000 after buying an additional 30,042 shares in the last quarter. RA Capital Management L.P. grew its stake in shares of Monopar Therapeutics by 30.5% in the fourth quarter. RA Capital Management L.P. now owns 667,207 shares of the company's stock worth $43,569,000 after acquiring an additional 156,000 shares in the last quarter. Siren L.L.C. grew its stake in shares of Monopar Therapeutics by 27.2% in the first quarter. Siren L.L.C. now owns 270,118 shares of the company's stock worth $14,800,000 after acquiring an additional 57,820 shares in the last quarter. ADAR1 Capital Management LLC grew its stake in shares of Monopar Therapeutics by 13.0% in the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company's stock worth $14,480,000 after acquiring an additional 30,370 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new stake in shares of Monopar Therapeutics during the third quarter worth $18,904,000. Institutional investors and hedge funds own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source